FuturoProssimo
No Result
View All Result
Contact
  • Tech
  • Medicine
  • Society
  • Ambience
  • Spazio
  • Transportation
  • concepts
  • H+
Thursday, April 22, 2021

   Coronavirus News >>

Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish
FuturoProssimo
No Result
View All Result

Read in:
Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

November 9, 2019

The drug that blocks glutamine slows down the tumor

Gianluca Ricciodi Gianluca Riccio
in Medicine
Send to FacebookPin on PinterestSend on TwitterSend on Whatsappon Linkedin
slow down the tumor

Jonathan Powell and Barbara Slusher of Johns Hopkins Medicine with a sample of the compound

By hitting glutamine, the team was able to slow down the tumor and alter the metabolism of the tumor microenvironment, "awakening" the immune system.

A research team from the Johns Hopkins Cancer Center has developed a critically important compound. It blocks the metabolism of glutamine, an amino acid involved in digestive processes, slows tumor growth, and alters the tumor microenvironment. Not only that: it promotes the production of resistant and highly active anticancer T cells.

"In theory, this tumor-slowing compound can be used in various types of neoplasia," says Jonathan Powell, at the head of the study published online on 7 November on Science.

By targeting glutamine metabolism, we were not only able to inhibit tumor growth and change the tumor microenvironment, but also to alter T-cells in a way that greatly improved cancer immunotherapy.

Jonathan Powell, associate director of Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Kimmel Cancer Center

Although glutamine metabolism is a component of all cells in the body, the DON drug selectively targets cancer cells because they are the "hungriest" for glutamine, Powell said. 

Maybe you are also interested

Glioblastoma, breakthrough in the treatment of this dangerous brain cancer

First human tests of the brain cancer vaccine completed

A new method measures metabolism from the breath

Regenerating therapy, we are now one step away: there are just 5 years left.

"What is emerging in metabolic therapy (this is why it is so important) is that a treatment like ours becomes selective because it preferably affects the cells that have the greatest demand."

Powell and colleagues tested the drug, nicknamed DON JHU083, in laboratory sessions on mice with colon cancer, lymphoma and melanoma.

JHU083: the results of an aspiring cancer killer.

"At the beginning our thought was that if we had addressed the metabolism of the tumor we would have achieved two objectives: slow down tumor growth and alter the tumor microenvironment", he claims Powell. 

The tumor microenvironment (i.e. the cells, blood vessels and nutrients found in tissues adjacent to tumors) is very hostile to the immune response. It is usually acidic, hypoxic and nutrient-depleted. Basically it is an "immune system" that defends cancer ... from the cure.

In mice, treatment with JHU083 led to a significant reduction in tumor growth and improved survival in many types of cancer. The metabolism of cancer cells is literally derailed. Its effects on the tumor microenvironment are devastating. In some mice, treatment with JHU083 alone led to lasting cures. 

Easier to heal, more difficult to get sick again

These cures were facilitated because metabolic therapy triggered the natural antitumor immune response. When the researchers replenished these cancer-free mice with new tumors, they found that nearly all of them rejected the new tumor. This suggests that the JHU083 treatment had produced a powerful immune memory to recognize and attack the new tumor.

The group also showed that treating the tumors with JHU083 improved the efficacy of adoptive cell therapy. It is a type of immunotherapy in which immune T cells are collected and grown in large numbers in the laboratory before being administered to patients to increase the immune response against cancer. 

Potentially, tumors that develop metabolic pathways to avoid the impacts of JHU083 could find themselves in a "dead end," Powell said. "By adding an additional metabolic antagonist, you could potentially eliminate even resistant tumors."

tags: cancerglutamineMetabolismtumor
Previous post

Doctors announce the success of the first, er, penis transplant

Next article

Pharmaceutical company announces: we have HIV and AIDS cure

Collaborate!

We are open to visions about the future. Submit an article, disclose the results of a search or scientific discoveries, shows points of view on a theme, tells about a change.

Contact us

Most read of the week

  • US intelligence analyzes the future, and it doesn't look good at all

    US intelligence analyzes the future, and it doesn't look good at all

    136 shares
    Share 54 Tweet 34
  • Plastic rains, still silence from the institutions

    30 shares
    Share 12 Tweet 7
  • The whitest white paint there is is even whiter (and cools)

    28 shares
    Share 11 Tweet 7
  • Monoclonal antibodies, treatment makes teeth grow back: animal tests

    45 shares
    Share 17 Tweet 11
The last
Technology

VR Dating: Will Virtual “First Date” One Day Be Mainstream?

Ambience

In American honey there are still traces of nuclear tests from the 50s and 60s

Robotica

Barney: the robot bartender is also ready to shake cocktails

Technology

NOSEiD, the app that finds lost dogs by recognizing them by their nose

archive

Next article
Pharmaceutical company announces: we have HIV and AIDS cure

Pharmaceutical company announces: we have HIV and AIDS cure

Facebook

Instagram

Telegram

Twitter

Clubhouse

Near future

Futuroprossimo.it is an Italian futurology resource open since 2006: every day news about the near future. Scientific discoveries, medical research, prototypes, concepts and predictions about the future for free.

Tag

Ambience Architecture Club Communication concepts Advice Economy Energy Events Gadgets The future of yesterday The newspaper of tomorrow Italy Next Medicine Military Weather Robotica Society Spazio Technology transhumanism Transportation Video

The author

Gianluca Riccio, copywriter and journalist - Born in 1975, he is the creative director of an advertising agency, he is affiliated with the Italian Institute for the Future, World Future Society and H +, Network of Italian Transhumanists.

Home / Author / IDEA / archive / Promo on FP

Collaborate! Are you interested in writing a post on Futuroprossimo? Click here for contacts.

Categories

Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.
© 2021 Futuroprossimo

  • Home
  • Contact
  • archive
  • Technology
  • Medicine
  • Transportation
  • Weather
  • Society
  • Ambience
  • transhumanism

© 2021 Futuroprossimo - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

This site uses cookies. By continuing to read it, you consent to their use.